We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.29% | 3.51 | 3.02 | 4.00 | - | 412 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 7.78 | 10.33M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/4/2024 13:50 | When are this shower planning on giving shareholders a ROI.???? | peverill | |
22/4/2024 14:38 | #92891 Pictures? | dominiccummings | |
22/4/2024 13:48 | Lovely tight spread (:- | goggin | |
22/4/2024 10:17 | Is that why the share price has risen Barry? | dominiccummings | |
22/4/2024 09:41 | I dont imagine I am the only avatar to note that there hasn't been a single trade since 18th April. | barry evans | |
18/4/2024 18:19 | I see the crack pipe is out again on the educated Fred. | peverill | |
18/4/2024 16:09 | If there is even a sniff of value in any of prm patents then the share will explode. | 049balt | |
18/4/2024 14:27 | Good afternoon, GlennRCharles. | barry evans | |
18/4/2024 13:20 | Someone hit the buy button by mistake? | glennrcharles | |
17/4/2024 15:54 | Much the same here.How is Mariola still in a job given 4 years of no progress,in fact she has taken the company back 10 years. | peverill | |
17/4/2024 12:18 | Radio silence on the LSE board, I note. Nothing, not even after the dire results. | barry evans | |
15/4/2024 17:54 | Hugh volume today though362 shares at 3.72p ? 9.96 gross - charges, ~ £5Don't get overwhelmed though by this serious investment: -) | goggin | |
15/4/2024 09:29 | yet anther p-tau 17 blood test hits the market Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation can someone get Pike the phone number for #patentlawyers4U (no win no fee) | elpirata | |
12/4/2024 21:18 | He wants to write it off,like the rest of us have had to do,due to his leadership and business acumen. | peverill | |
12/4/2024 16:51 | I note that cjp's loan with interest accruing is now £11.235m & prm has an mcap just over £9m | elpirata | |
12/4/2024 12:35 | normal service resumed, zilch trades, not a sausage STRONG DONT BUY | elpirata | |
11/4/2024 11:09 | The "top coins" rubbish below is nothing to do with me - I would delete it if I could I say goatherd thats a bit strong isnt it? We all know pools has a tendency to wander down the garden path but 'rubbish?' Will you be banning the avatar next? | elpirata | |
10/4/2024 15:11 | And may I ask we vote against any of these being reinstated for another 12 months.tia. | peverill | |
10/4/2024 15:08 | Should tank about 16.25. | peverill | |
10/4/2024 14:48 | I'll stick to looking at the share price and long term chart, thanks all the same. | barry evans | |
10/4/2024 14:45 | Unfortunately, you should pay far more attention, as your hatred for everything PRM completely blinds you. Proteome Sciences have stated AD license deals publicly. You can find out where yourself. STRONG BUY | wasjobber | |
10/4/2024 13:48 | Odd that they should make no mention of this in either the Profit warning or those dire results and downbeat supporting statements, no? | barry evans | |
10/4/2024 13:29 | Proteome Sciences have only recently received these important new patent grants. The area is complex and just because biomarkers are currently being used by other companies, it does not mean they won't require a license from Proteome Sciences moving forward. I think Proteome Sciences will get license deals (and associated back payments) for Alzheimers disease and cancer soon. | wasjobber |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions